Relapsed follicular lymphoma

ZYDELIG® is the most prescribed therapy for 3rd-line+ follicular lymphoma*

View efficacy

*IntrinsiQ, May 2015-December 2017.

Relapsed CLL

Updated results from final analysis of the pivotal trial 

View efficacy

 

ZYDELIG safety profile

Safety profile informed by multiple clinical studies

View details

ZYDELIG® AccessConnect®

Nurse support and financial assistance for ZYDELIG patients

Learn more

ZYDELIG is a PI3Kδ inhibitor indicated for

FL
Relapsed follicular lymphoma in patients who have received at least two prior systemic therapies
CLL
Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities
SLL
Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies

Accelerated approval was granted for follicular lymphoma and SLL based on overall response rate. An improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.

ZYDELIG is not indicated or recommended for first-line treatment of any patient or in combination with bendamustine and/or rituximab for the treatment of follicular lymphoma.

PI3Kδ=phosphatidylinositol 3-kinase delta.

Reference:

  1. ZYDELIG® (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; rev January 2018.